Yang H, Raymer K, Butler R, et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial[J]. Am Heart J, 2006,152(5): 983-990.
[1]
Auerbach A D, Goldman L. β-Blockers and reduction of cardiac events in noncardiac surgery: scientific review [J]. JAMA, 2002, 287(11): 1435-1444.
[2]
Lüscher T F, Gersh B, Landmesser U, et al. Is the panic about beta-blockers in perioperative care justified? [J]. Eur Heart J, 2014, 35(36): 2442-2444.
[3]
Prys-Roberts C, Fo?x P, Biro G P, et al. Studies of anaesthesia in relation to hypertension. V. Adrenergic beta-receptor blockade[J]. Br J Anaesth, 1973, 45(7): 671-681.
[14]
Beattie W S, Wijeysundera D N, Karkouti K, et al. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials[J]. Anesthesia and analgesia, 2008,106(4):1039-1048.
[4]
Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia[J]. Anesthesiology, 1998, 88(1): 7-17.
[15]
Devereaux P J, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial[J]. Lancet, 2008, 371(9627): 1839-1847.
[5]
Jenkins N P, Keevil B G, Hutchinson I V, et al. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease [J]. Am J Med, 2002, 112(4): 269-274.
[16]
Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and Fluvastatin for the Reduction of Perioperative Cardiac Mortality and Myocardial Infarction in Intermediate-Risk Patients Undergoing Noncardiovascular Surgery[J]. Annals of Surgery, 2009,249(6):921-926.
[6]
Anzai T, Yoshikawa T, Takahashi T, et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction [J]. Cardiology, 2003, 99(1): 47-53.
[17]
Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study[J]. BMJ, 2005, 331(7522):932.
[7]
Yeager R A, Moneta G L, Edwards J M, et al. Reducing perioperative myocardial infarction following vascular surgery. The potential role of beta-blockade[J]. Archiv Surg, 1995,130(8): 869-872.
[18]
Lindenauer P K, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery[J]. N Engl J Med, 2005, 353(4): 349-361.
[8]
Mangano D T, Layug E L, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery [J]. N Engl J Med, 1996, 335(23):1713-1720.
[9]
Poldermans D, Boersma E, Bax J J, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery [J]. N Engl J Med, 1999,341(24): 1789-1794.
[19]
Devereaux P J, Beattie W S, Choi P T, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and Meta-analysis of randomised controlled trials[J]. BMJ, 2005, 331(7512): 313-321.
[10]
Yang X Y, Wu X M, Wang S, et al. Effects of metoprolol on perioperative cardiovascular events in patients with risk or at high risk for coronary artery disease undergoing non-cardiac surgery[J]. Zhonghua Yi Xue ZaZhi, 2008, 88(21):1476-1480.
[11]
Urban M K, Markowitz S M, Gordon M A, et al. Postoperative prophylactic administration of beta-adrenergic blockers in patients at risk for myocardial ischemia[J]. Anesthesia and Analgesia, 2000, 90(6): 1257-1261.
[20]
Fleisher L A, Beckman J A, Brown K A,et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines[J]. Circulation, 2009, 120(21): e169-276.
[12]
Juul A B, Wetterslev J, Gluud C, et al. Effect of perioperative β blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial[J]. BMJ, 2006, 332(7556):1-7.
[21]
Fleisher L A, Beckman J A, Brown K A, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2007, 50(17): e159-241.
[13]
Yang H, Raymer K, Butler R, et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial[J]. Am Heart J, 2006,152(5): 983-990.
[22]
Kristensen S D, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)[J]. Eur J Anaesthesiol, 2014, 31(10): 517-573.
[23]
Fleisher L A, Fleischmann K E, Auerbach A D, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J]. J Nucl Cardiol, 2015,22(11): 162-215.
[14]
Beattie W S, Wijeysundera D N, Karkouti K, et al. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials[J]. Anesthesia and analgesia, 2008,106(4):1039-1048.
[15]
Devereaux P J, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial[J]. Lancet, 2008, 371(9627): 1839-1847.
Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and Fluvastatin for the Reduction of Perioperative Cardiac Mortality and Myocardial Infarction in Intermediate-Risk Patients Undergoing Noncardiovascular Surgery[J]. Annals of Surgery, 2009,249(6):921-926.
[25]
Bauer S M, Cayne N S, Veith F J, et al. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery[J]. J Vascul Surg, 2010, 51(1): 242-251.
[17]
Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study[J]. BMJ, 2005, 331(7522):932.
[26]
Winchester D E, Pepine C J. Usefulness of beta blockade in contemporary management of patients with stable coronary heart disease[J]. Am J Cardio, 2014,114(10): 1607-1612.
[18]
Lindenauer P K, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery[J]. N Engl J Med, 2005, 353(4): 349-361.
[27]
Kalra P R, Morley C, Barnes S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study[J]. Int J Cardiol, 2013,167(6): 2695-2699.
[19]
Devereaux P J, Beattie W S, Choi P T, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and Meta-analysis of randomised controlled trials[J]. BMJ, 2005, 331(7512): 313-321.
[28]
Ko D T, Hebert P R, Coffey C S, et al. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction[J]. JAMA, 2002, 288(3): 351-357.
[20]
Fleisher L A, Beckman J A, Brown K A,et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines[J]. Circulation, 2009, 120(21): e169-276.
[29]
Shammash J B, Trost J C, Gold J M, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients[J]. Am Heart J, 2001,141(1):148-153.
[21]
Fleisher L A, Beckman J A, Brown K A, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2007, 50(17): e159-241.
[22]
Kristensen S D, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)[J]. Eur J Anaesthesiol, 2014, 31(10): 517-573.
[23]
Fleisher L A, Fleischmann K E, Auerbach A D, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J]. J Nucl Cardiol, 2015,22(11): 162-215.
Bauer S M, Cayne N S, Veith F J, et al. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery[J]. J Vascul Surg, 2010, 51(1): 242-251.
[26]
Winchester D E, Pepine C J. Usefulness of beta blockade in contemporary management of patients with stable coronary heart disease[J]. Am J Cardio, 2014,114(10): 1607-1612.
[27]
Kalra P R, Morley C, Barnes S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study[J]. Int J Cardiol, 2013,167(6): 2695-2699.
[28]
Ko D T, Hebert P R, Coffey C S, et al. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction[J]. JAMA, 2002, 288(3): 351-357.
[29]
Shammash J B, Trost J C, Gold J M, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients[J]. Am Heart J, 2001,141(1):148-153.
2015, Vol. 26 
